Aktieanalys

OssDsign: Value accretive shift in strategy - ABG

ABG Sundal Collier Publicerad: 28 Sep 2023 10:18

Value accretive shift in strategy
Directed share issue of SEK 150m
Fair value range up to SEK 9-15 (from 6-15)

Shift in strategy

We believe the change in strategy makes perfect strategic and financial sense, given the difference in growth rate and gross margin between the two products. The exit from the cranial implant business lowers the overall cost base by 18-24% (based on our 2023e opex forecast), as the company is becoming a pure orthobiologics company with out-sourced production, and only focusing on the US market. In addition, we also belive the change in strategy and exit from the cranial implant business makes OssDsign a more likely take-over candidate once commercially validated in the coming years.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossdsign/Equity-research/2023/9/ossdsign---analyst3/

Nyheter om OssDsign

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!